Mission Therapeutics appoints Anker Lundemose as Chief Executive Officer

13-Jan-2015 - United Kingdom

Mission Therapeutics announced the appointment of Dr Anker Lundemose MD PhD as Chief Executive Officer.

Dr Lundemose brings extensive experience to Mission at a pivotal stage in the Company’s evolution, as it transitions from discovery to development. In a biopharma career spanning over two and a half decades, he was most recently CEO of Norwegian vaccine company Bionor Pharma ASA, and previously co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, subsequently reversed into OSI.  The Mission appointment constitutes Dr Lundemose’s fourth CEO position. As a CEO, Executive Vice President, co-founder and/or board member, he has been involved in a total of six biotech exits/IPOs.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances